Hepatology

Top Medical News
Elaine Soliven, Yesterday
Treatment with nidufexor led to significantly reduced serum alanine aminotransferase (ALT) levels and hepatic fat fraction in patients with nonalcoholic steatohepatitis (NASH), according to a phase II study presented at ILC 2020.
Elvira Manzano, 2 days ago
A repeat fibrosis-4 (FIB-4) test ably identifies individuals at greatest risk for liver cirrhosis in a new study.
5 days ago
In patients with decompensated cirrhosis, β-blockers trigger a stronger systemic haemodynamic response and exert a weaker portal pressure-lowering effect, a recent study has found.
6 days ago
A novel nomogram that includes liver stiffness measurements may help predict postoperative complications in hepatocellular carcinoma (HCC) patients, a recent study has found.
Roshini Claire Anthony, 21 Sep 2020

Daily albumin infusion to achieve serum albumin levels of 30 g/L did not reduce the risk of infection, renal dysfunction, or mortality in individuals with acute decompensated cirrhosis, according to results of the ATTIRE* study presented at ILC 2020.

16 Sep 2020
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 14 Sep 2020
The novel combination regimen comprising the immune checkpoint inhibitors (ICIs) durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) showed a favourable safety profile and clinical activity for advanced hepatocellular carcinoma (HCC), according to detailed safety data presented at ESMO GI 2020.
Special Reports
16 Sep 2020
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

Conference Reports
Elaine Soliven, 30 Sep 2020
Treatment with nidufexor led to significantly reduced serum alanine aminotransferase (ALT) levels and hepatic fat fraction in patients with nonalcoholic steatohepatitis (NASH), according to a phase II study presented at ILC 2020.
Elvira Manzano, 29 Sep 2020
A repeat fibrosis-4 (FIB-4) test ably identifies individuals at greatest risk for liver cirrhosis in a new study.
Roshini Claire Anthony, 21 Sep 2020

Daily albumin infusion to achieve serum albumin levels of 30 g/L did not reduce the risk of infection, renal dysfunction, or mortality in individuals with acute decompensated cirrhosis, according to results of the ATTIRE* study presented at ILC 2020.

Audrey Abella, 14 Sep 2020
The novel combination regimen comprising the immune checkpoint inhibitors (ICIs) durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) showed a favourable safety profile and clinical activity for advanced hepatocellular carcinoma (HCC), according to detailed safety data presented at ESMO GI 2020.
Elaine Soliven, 11 Sep 2020
Treatment with an FGF19 analogue aldafermin, previously known as NGM282, led to a significantly reduced liver fat content (LFC) in patients with nonalcoholic steatohepatitis (NASH), according to a study presented at ILC 2020.
Roshini Claire Anthony, 10 Sep 2020

In virologically suppressed patients with chronic hepatitis B virus (HBV) infection, switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) did not affect their rates of viral suppression, according to the final 96-week analysis of a phase III study.

Pearl Toh, 10 Sep 2020
The combination therapy of cilofexor (CILO) and firsocostat (FIR) missed the primary endpoint but achieved improvements in other secondary parameters including fibrosis markers, disease activity, and liver function in patients with fibrosis due to NASH*, according to the ATLAS trial presented at digital ILC 2020.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download